Press Releases for OPTR

Press Releases
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results
Optimer Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
Optimer Pharmaceuticals to Raise $32.9 Million in Registered Direct Offering
Optimer Pharmaceuticals to Accelerate European Filing of Fidaxomicin (OPT-80)
Optimer Pharmaceuticals Announces Publication in Peer-Reviewed Journal about Prulifloxacin’s Antibacterial Activity against Infectious Diarrhea Producing Bacteria
Optimer Pharmaceuticals Announces Positive Results from Second Phase 3 Study of Prulifloxacin for Infectious Diarrhea in Travelers
Optimer Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
Optimer Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
Optimer Pharmaceuticals Reports Positive Data from its North American Phase 3 CDI Study of OPT-80
Optimer Pharmaceuticals Reports Third Quarter 2008 Financial Results
Optimer Pharmaceuticals to Present at Oppenheimer Annual Healthcare Conference
Data from Optimer Pharmaceuticals' Prulifloxacin Phase 3 Trial in Traveler's Diarrhea and Strain Typing Data from OPT-80 Study to be Presented at ICAAC/IDSA Annual Meeting
Optimer Pharmaceuticals to Present at Two Upcoming Investor Conferences - Sep 10 2008 8:12AM
Optimer Pharmaceuticals Completes Enrollment in Second Prulifloxacin Phase 3 Clinical Trial
Optimer Pharmaceuticals to Present at BioCentury NewsMakers Conference
Optimer Pharmaceuticals Reports Second Quarter 2008 Financial Results
Optimer Pharmaceuticals to Present at August 2008 Investor Conferences
Optimer Pharmaceuticals Completes $14.8 Million Registered Direct Offering
Optimer Pharmaceuticals Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium difficile Infection
Optimer Pharmaceuticals to Raise $12.2 Million in Registered Direct Offering
Optimer Pharmaceuticals Announces Change to Board of Directors
Optimer Pharmaceuticals Announces Positive Results in Prulifloxacin Phase 3 Study
Optimer Reports Additional Data on Investigational Compound OPT-80 at Anaerobe 2008 Congress
Optimer Pharmaceuticals to Present at Two Upcoming Investor Conferences - Jun 17 2008 10:01AM
Optimer to Present Additional Data from OPT-80 Phase 2A Study for Clostridium difficile Infection at Anaerobe 2008 Congress
Optimer Pharmaceuticals to Present at Needham Biotechnology & Medical Technology Conference
Optimer Pharmaceuticals Receives Polymorph Patent for Lead Product Candidate OPT-80
Optimer Pharmaceuticals Reports First Quarter 2008 Financial Results - Jun 2 2008 12:51AM
Optimer Pharmaceuticals to Present at Upcoming Investor Conferences - Jun 2 2008 12:51AM
Clostridium difficile Infection 'Epidemic' Leads to Calls for Emerging Next-Generation Therapies
Optimer Pharmaceuticals Sponsors ECCMID Symposium on Clostridium Difficile-Associated Disease: Current Treatments and Challenges
Optimer Pharmaceuticals Receives Notice of Allowance for OPT-80 Patent Application
Optimer Pharmaceuticals Announces Peer-Reviewed Publication of OPT-80 Phase 1 Clinical Results for the Treatment of Clostridium Difficile Infection